Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Quality of life in hypoparathyroidism.

Literature DB >> 29181618

Quality of life in hypoparathyroidism.

Lars Rejnmark¹.

Abstract

Entities: Disease

Mesh：

Substances：
Parathyroid Hormone

Year: 2017 PMID： 29181618 DOI： 10.1007/s12020-017-1479-y

Source DB: PubMed Journal: Endocrine ISSN： 1355-008X Impact factor: 3.633

× No keyword cloud information.

8 in total

1. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial.

Authors: T Sikjaer; L Rolighed; A Hess; A Fuglsang-Frederiksen; L Mosekilde; L Rejnmark
Journal: Osteoporos Int Date: 2014-04-01 Impact factor: 4.507

Review 2. Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review.

Authors: Matthias Büttner; Thomas J Musholt; Susanne Singer
Journal: Endocrine Date: 2017-08-18 Impact factor: 3.633

3. Concurrent Hypoparathyroidism Is Associated With Impaired Physical Function and Quality of Life in Hypothyroidism.

Authors: Tanja Sikjaer; Emil Moser; Lars Rolighed; Line Underbjerg; Lise Sofie Bislev; Leif Mosekilde; Lars Rejnmark
Journal: J Bone Miner Res Date: 2016-03-31 Impact factor: 6.741

4. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium.

Authors: Karen K Winer; Chia Wen Ko; James C Reynolds; Karen Dowdy; Meg Keil; Donna Peterson; Lynn H Gerber; Charles McGarvey; Gordon B Cutler
Journal: J Clin Endocrinol Metab Date: 2003-09 Impact factor: 5.958

5. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism.

Authors: K K Winer; J A Yanovski; B Sarani; G B Cutler
Journal: J Clin Endocrinol Metab Date: 1998-10 Impact factor: 5.958

6. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.

Authors: Michael Mannstadt; Bart L Clarke; Tamara Vokes; Maria Luisa Brandi; Lakshminarayan Ranganath; William D Fraser; Peter Lakatos; Laszlo Bajnok; Roger Garceau; Leif Mosekilde; Hjalmar Lagast; Dolores Shoback; John P Bilezikian
Journal: Lancet Diabetes Endocrinol Date: 2013-10-07 Impact factor: 32.069

7. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy.

Authors: Natalie E Cusano; Mishaela R Rubin; Donald J McMahon; Dinaz Irani; Laura Anderson; Elizabeth Levy; John P Bilezikian
Journal: J Clin Endocrinol Metab Date: 2014-06-30 Impact factor: 5.958

8. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.

Authors: Tanja Sikjaer; Anne Kristine Amstrup; Lars Rolighed; Soren Geill Kjaer; Leif Mosekilde; Lars Rejnmark
Journal: J Bone Miner Res Date: 2013-10 Impact factor: 6.741

8 in total

6 in total

1. Assessing the Patient Experience of Hypoparathyroidism Symptoms: Development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom).

Authors: Meryl Brod; Laura Tesler Waldman; Alden Smith; David Karpf
Journal: Patient Date: 2020-04 Impact factor: 3.883

Quality of life in hypoparathyroidism.

1. Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial.

Review 2. Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review.

3. Concurrent Hypoparathyroidism Is Associated With Impaired Physical Function and Quality of Life in Hypothyroidism.

4. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium.

5. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism.

6. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.

7. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy.

8. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.

1. Assessing the Patient Experience of Hypoparathyroidism Symptoms: Development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom).

2. Postoperative Chronic Hypoparathyroidism and Quality of Life After Total Thyroidectomy.

3. What is the experience of our patients with transient hypoparathyroidism after total thyroidectomy?

4. Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPES-Impact).

5. Psychometric validation of the Hypoparathyroidism Patient Experience Scales (HPES).

6. A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults.